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1. Introduction 
Gastric and esophageal cancers are one of the most aggressive malignancies worldwide. 
Complete surgical resection offers the only chance of cure but many cases are presented at 
advanced stages or recur even after R0 resections. In gastric cancer (GC), 5-year survival 
rates (SRs) of stages II and III after curative resection range respectively from 30%-49% and 
10-20% in Western countries, and respectively 70-80% and 40-50% in Japan and Korea (Fujii 
et al., 1999; Hundahl et al., 2000; J.P.Kim et al., 1998; Shimada et al., 1999). With regard to 
esophageal cancer (EC), the 5-year SRs in older series were 14-20% in the United States 
(Daly et al., 1996; Ries et al., 2007) and ranging from 3 to 11% in European countries, with an 
average of 10% (Faivre et al., 1998) while they improved to 42% in a recent series (Rice et al., 
2009; Ruol A et al., 2009), which is comparable to those (36-46%) after an esophagectomy in 
Japan (The Japan Esophageal Society). Even in Japan, however, T3 or stage III EC, the most 
frequently encountered tumor depth or tumor stage, has exhibited respectively lower 5-year 
SRs of 27-29% and 17-20% after esophagectomy (Ando et al., 2000; The Japan Esophageal 
Society). Although stage-specific survival rates differ between reports from Western and 
Asian institutions, the survival decline according to the stage progression suggests that 
recurrence does occur even for those who undergo curative resection. Furthermore, a more 
extended (>D2) lymph node dissection (LND) in GC unfortunately fails to improve survival 
outcomes (Sasako et al., 2008).  
Such disappointing treatment results in GC and EC even in Japan -where aggressive LND 
has been performed- have reminded researchers a plateau effectiveness of, and little 
likelihood of further improvement by, surgical therapy only. These facts have encouraged 
physicians to establish more effective multimodal strategies to improve survival, including 
newly developed regimens incorporating molecular targeting agents as well as to determine 
candidate molecules or genes that could help establish individualized therapies. These 
multimodal therapies have mainly consisted of chemotherapy (CTx), radiotherapy (RTx), 
and chemoradiotherapy (CRTx) administered after curative resection (adjuvant settings), or 
for recurrent or inoperable diseases (advanced settings), or before surgical resection 
(neoadjuvant settings). Recently, CRTx has become a focus of research, because of the 
radiosensitizing properties of some chemotherapeutic agents that could potentiate the 
anticancer activities of both CTx and RTx (Kleinberg et al., 2007).  
Table lists the theoretical advantages and disadvantages of adjuvant and neoadjuvant 
treatments (Rice et al., 2003). Adjuvant and neoadjuvant treatments require balancing 
advantages and disadvantages to maximize treatment effects. This chapter focuses on past, 
current, and potential future directions in the field of multimodal therapies in GC and EC.  
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  Advantages Disadvantages 
Adjuvant 
treatment 
Prevention of potential recurrence from 
occult micrometastasis which would 
become overt postoperatively.  
Inability to assess final treatment 
effects until diseases recur.  
 
Less consideration for increase in 
morbidity and mortality that would be 
sometimes harm in case of neoadjuvant 
treatment.  
Destruction of vasculature that 
decreases delivery of drugs or 
oxygen compromising CTx and/or 
RTx effects. 
 
Treatment decision based on the full 
staging information, which can avoid 
unnecessary treatment in patients who 
may not otherwise require it, i.e., in 
patients with earlier stage of the disease 
than expected.  
Preclusion of early commencement 
of therapy if patient recovery 
delays due to postoperative 
complications or reduced 
functional status. Requirement of 
longer period to recover from 
surgery allows tumor cells for 
further growth. 
 
Especially in EC, relief of tumor-
associated complaints such as dysphagia 
or alimentary support by surgically-
placed feeding tube, allowing for better 
tolerance of postoperative therapy.  
In RTx, removal of target that make 
definition of radiation field more 
difficult.  
Neoadjuvant 
treatment 
Increased surgical R0 resection rate by 
downstaging which would otherwise 
have been regarded as incurable (R1/R2 
resection). 
Surgical delay due to toxicities that 
would cancel the potential survival 
benefit of responders.  
 
Early elimination of undetectable 
micrometastasis. 
Loss of opportunity to undergo 
surgery by tumor growth during 
treatment period in nonresponders. 
 
Intact vasculature that maintains 
accessibility of drugs to the tumor bed 
and oxygenation, realizing more effective 
CTx and/or RTx. 
No reliable methods available to 
predict tumor response that could 
discriminate responders and non-
responders before treatment. 
 
Determination of tumor and patient 
specific chemo(radio)sensitivity that 
would be applicable to postoperative 
treatment. 
Increased surgical complaints due 
to preoperative treatment-related 
toxicities. 
 
Possibility to administer a more intensive 
regimen because of the maintained 
physical and nutritional state. The same 
regimen would become more toxic if 
given postoperatively due to surgical-
related complication.  
Preclusion of effective regimen due 
to dysphagia or tumor related 
worse nutritional state, especially 
in EC. 
    
Possibility of overtreatment for 
early stage tumor because 
treatment is based on clinical stage 
that is not necessarily accurate. 
Table 1. Advantages and disadvantages of adjuvant and neoadjuvant treatment [Rice TW, et 
al. 2003]. 
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2. General considerations 
In consideration of the establishment of multimodal therapies against GC and EC, one 
should bear in mind the difference in surgical treatment and pathology between Japan and 
the West. First, the scope of LND influences local tumor control rate and postoperative 
survival. A wider scope of LND has the theoretical potential to reduce local recurrence rates, 
which may improve postoperative survival. Second, it is also a fact that a wider scope of 
LND increases postoperative morbidity and mortality, which may cancel the anticipated 
survival benefit of LND. This phenomenon is especially observed in the West, providing 
one reason for the difference in the standard scope of LND between here and Japan. As a 
result, for GC, the standard scope of LND is a D2 (second-tier node dissection) in Japan but 
a D1 (first-tier node dissection) in the West, and for EC, the routinely performed node 
clearance encompasses three fields (cervical, thoracic, and abdominal) or at least any two of 
the three fields in Japan, while it encompasses a limited area in the West. Since the effect of 
hospital volume on a perioperative mortality hazard is larger than those on hazards for 
death at 5 years postoperatively (Bilimoria et al., 2008; Birkmeyer et al., 2002), the 
perioperative patient control reflects the subsequent overall survival; thus, LND by 
specialists is now an important issue. Third, a wider scope of LND results in a more accurate 
nodal staging than a narrower one. Therefore, under conditions of a limited extent of LND, 
judgement regarding R0 resection is not always accurate, and resections deemed R0 might 
sometimes be actually equivalent to R1 resection. For example, in a Dutch trial, 38% of GC 
patients classified as stage II on D1 dissection were reclassified as stage IIIA on D2 
dissection (Bunt,1995). This discordance is reflected by the stage migration phenomenon 
which implies that a narrower scope of LND results in a significant risk of understaging. 
Therefore, results of clinical trials of multimodal therapies are undoubtedly influenced if 
they recruit such understaged patients. Fourth, the scope of LND depends on the 
pathological characteristics of the tumor. With regard to EC, adenocarcinoma is observed at 
a substantial ratio (43-56%) in the United States (Daly et al., 1996; Trivers et al., 2008), while 
squamous cell cancer comprises a majority in Japan (The Japan Esophageal Society), the 
incidences twice those of the United States (90% vs. 38%) (Trivers et al., 2008). Such 
histological differences reflect tumor location and surgical approach. In Japan, the 
incidences of middle and lower third thoracic EC were respectively 50% and 25% (The Japan 
Esophageal Society), whereas those in the United States were respectively 25% and 50% 
(Daly et al., 1996). Considering that upper thoracic or cervical nodal involvement occurs 
more frequently in the middle third than lower third thoracic EC, such histological and 
topographical differences also influence surgical approach and ultimately the scope of LND. 
In Japan, a right thoracotomy is a main approach while a transhiatal approach is considered 
in the West (Hulscher et al., 2001). Finally, the different stances in surgical therapy between 
Japan and the West reflect the different stances of multimodal therapies. Since a wider scope 
of LND is more effective in local tumor control than a limited one, CTx rather than CRTx 
has been developed in Japan for the purpose of preventing systemic relapse rather than local 
recurrence, whereas CRTx rather than CTx has been developed in the West for the purpose 
of preventing both local and systemic relapse.  
3. Gastric cancer 
3.1 Adjuvant setting 
Many randomized controlled trials (RCTs) have been conducted to assess the advantage of 
adjuvant CTx on survival compared with surgery alone. However, they have shown mixed 
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results and have been mostly disappointing. The difficulties in making definitive 
conclusions concerning the significance of adjuvant CTx are accounted for -at least in part- 
by the small size of the studies and suboptimal CTx regimens. Many trials recruited 
relatively small numbers of patients -usually less than 200- and were therefore inadequate to 
detect clinically significant survival differences between the CTx arm and surgery alone 
arm. In addition, many CTx regimens employed old types of drug with low response rates 
(RRs) and short durations of response. Therefore, the negative results of most previous 
clinical trials do not necessarily mean that the adjuvant CTx does not work.  
Several meta-analyses of adjuvant trials have been published (Earle & Maroun, 1999; 
GASTRIC Group, 2010; Hermans et al., 1993; Hu et al., 2002; Janunger et al., 2002; Liu et al., 
2008; Mari et al., 2000; Oba et al., 2006; Panzini et al., 2002; Zhao & Fang, 2008) in order to 
overcome the drawbacks of small patient accrual and to assess any potential benefit by 
adjuvant therapy that may have been missed in the individual trials. Unfortunately, 
definitive evidence concerning benefits of adjuvant CTx is lacking, with results ranging 
from an odds ratio for death of 0.56-0.9 to no benefit. However, the first meta-analysis 
(Hermans et al., 1993), which failed to demonstrate a clear benefit of adjuvant CTx, was later 
updated by an inclusion of 318 patients who had been erroneously omitted from the initial 
analysis, resulting in a reduction of the odds ratio for death to a significant 0.82 (Hermans & 
Bonenkamp, 1994).  
Nevertheless, criticism still persists as to the methodologies applied in these meta-analyses 
that make this interpretation too complicated. For example, there was a great heterogeneity 
among individual studies in terms of quality of surgery, adjuvant therapy regimens 
administered, clinical stage, and intervals between surgery and the commencement of CTx. 
Accordingly, patient recruitment was not uniform within each meta-analysis. Some meta-
analyses included studies of palliative resections and curative resections, or studies of CTx, 
RTx, and immunotherapy together. The quality of surgery could not be evaluated because 
the scope of LND was not always clarified. Studies with old generation drug(s) and those 
with newer generation drug(s) were also included together. In addition, one meta-analysis 
(Hu et al., 2002) included a previous meta-analysis (Hermans et al., 1993).  
The most recent meta-analysis (GASTRIC Group, 2010), which was the first patient-level 
analysis, was published in the year 2010. It demonstrated both mortality and relapse hazard 
reduction by 18% each by adjuvant CTx. This trend was also reproduced irrespective of the 
number of CTx drugs (monochemotherapy and polychemotherapies). Furthermore, a 
survival improvement of 6% by CTx at 5 years postoperatively was maintained during the 
ensuing 5 years. These consecutive results of the meta-analyses suggest that the benefit of 
adjuvant CTx change from ‘none or inconclusive or borderline’ to ‘significant’. 
Subset metaanalysis have demonstrated inconsistent results, however. When Asian and 
non-Asian adjuvant trials were grouped together or analyzed separately, survival benefits 
were seen only in the non-Asian studies (Earle & Maroun, 1999), or only in the Asian studies 
(Janunger et al., 2002), or in both (Zhao & Fang, 2008). The extant metaanalyses are therefore 
difficult to interpret due to significant heterogeneity. Interestingly, in the pivotal Japanese 
RCT for adjuvant CTx (JCOG9206-1) (Nashimoto et al., 2003), the total recurrence rate at 69 
months was almost double in the surgery only arm than in the CTx arm (13.8% vs. 7.1%), 
indicating a possible role by CTx for the prevention of recurrence. Against these 
backgrounds, several large RCTs of postoperative or perioperative CTx have been 
conducted in Japan, the United States, and Europe, and each result has been recently 
published. 
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The ACTS-GC (Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer) trial is so far the 
largest adjuvant RCT conducted in Japan, in which oral S-1, a new generation of 
fluoropyrimidine derivative, was administered for 1 year as an adjuvant treatment 
(Sakuramoto et al., 2007). The survival benefit of S-1 at three years postoperatively has also 
been confirmed at 5 years (Sasako et al., 2010). The results are consistent with the previous 
metaanalysis demonstrating the survival advantage of oral fluoropyrimidine containing 
adjuvant regimen (Oba et al., 2006). Of note in this trial is that most of the recruited patients 
underwent D2 or a wider scope of LND, and even under such circumstances of qualified 
surgery, the oral fluoropyrimidine derivative alone was able to render benefits in an 
adjuvant setting. However, caution is required when these results are applied to clinical use. 
The subanalysis of the ACTS-GC trial revealed that survival benefit was maintained in 
stages II and IIIA GC but disappeared in stage IIIB. Such stage specific survival differences 
suggest that oral fluoropyrimidine alone lacks power to exhibit statistically meaningful 
survival advantages in more advanced stages. 
The phase III intergroup-0116 trial (INT0116) is one of the most important adjuvant trials 
against adenocarcinoma of the stomach or esophagogastric junction ever conducted in 
North America (Macdonald et al., 2001). The adjuvant treatment in this study was a CRTx 
consisting of fluorouracil, leucovorin, and extra-beam radiation delivered to the tumor bed 
with 2cm beyond the proximal and distal margins of resection as well as to the areas of 
regional draining lymph nodes. Adjuvant CRTx yielded a significant prolongation of 
disease free survival (DFS) and overall survival (OS) at 3 years postoperatively (Macdonald 
et al., 2001). More than six years of median follow-up confirmed no deterioration of survival 
over time (Macdonald et al., 2004), making this regimen optimal as the standard of care in 
the United States. However, there has also been some criticism directed towards this study.  
First, the extent of surgery performed in this study has been a focus of much debate. The 
trial has been criticized for the surgical undertreatment of patients: 54% and 36% of the 
patients in the trial respectively underwent a D0 and a D1 LND despite a recommendation 
of a D2 LND in the trial protocol. Such noncompliance clearly undermined survival and led 
to a high relapse rate of 64% in the surgery only arm after a median follow-up of 5 years, the 
results contrasting sharply with those of the JCOG9206-1 trial (Nashimoto et al., 2003). 
Considering that more than two thirds and 85% of the recruited patients respectively had 
T3/T4 diseases and were node positive, the survival benefit by CRTx seen in this study 
seemed to be simply a compensation for the control residual disease left by the inadequately 
limited surgery (D0 or D1), which could otherwise be resected by a D2 LND. Second, usage 
of 5FU as a radiosensitizer and chemotherapy of 5FU and leucovorin seemed appropriate at 
the time when INT-0116 was designed (in the 1980’s) and executed (in the 1990’s); however, 
new generation agents with a superior antitumor activity and greater radiosensitizing effect 
continue to be developed (Rice et al., 2003).  
As discussed in the General Considerations section, this context raises another important 
insight that outcomes of adjuvant therapy undoubtedly depend on the quality of surgery, in 
particular, on the scope of LND. The incidence of locoregional recurrence after curative 
resection has been higher in the West (Roviello et al., 2003) (45%) than in Japan (Maehara et 
al., 2000) (22%), suggesting a benefit from the routine performance of a D2 LND for local 
tumor control. Such a benefit is guaranteed by the safe performance of a D2 LND in Japan, 
with a 0-2.2% mortality rate (Fujii et al., 1999; Maruyama et al., 1987; Maruyama et al., 2006; 
Nashimoto et al., 2003; Sano et al., 2002). Indeed, in the JCOG9206-1 trial, 98% of the patients 
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underwent a D2 or greater LND, with just one (0.8%) postoperative death in the surgery 
only arm. The number of patients with local recurrence was two (1.6%) in the surgery only 
arm and none in the adjuvant treatment arm, suggesting a remarkable local control rate by 
the Japanese style D2 LND. Therefore, convinced of the benefit of a D2 LND, Japanese 
investigators have always been reluctant to conduct any trial comparing D2 with D1 LND. 
In contrast, operative mortality remains high within Europe, ranging between 5-16% 
(Lepage et al., 2010). Under these circumstances, the initial phase III trials conducted in the 
West demonstrated that a D2 LND provided neither survival improvements nor decreased 
relapse rates, and that it was even harmful in terms of a 43-46% morbidity and 10-13% 
mortality (Bonenkamp et al., 1995; Bonenkamp et al., 1999; Cuschieri et al., 1996; Cuschieri A 
et al., 1999; Hartgrink et al., 2004a; Songun et al., 2010). Such higher D2-associated morbidity 
and mortality were initially considered to nullify its potential survival benefit by local 
control; however, a subsequent long-term 15-year follow up of a Dutch trial observed 
significantly higher local recurrence rates and cancer-related death rates in D1 than in D2 
(Songun et al., 2010), leading the authors to conclude that a D2 LND has efficacy for local 
control and can be recommended for resectable GC, given that a safer, spleen-preserving D2 
LND is available. Subsequent studies have supported this procedure-related safety. Several 
nonrandomized trials have also demonstrated no differences in morbidity and mortality 
between a D1 and a D2 or wider LND (Bösing et al., 2000; Edwards et al., 2004; Danielson et 
al., 2007; Zilberstein et al., 2004). The RCTs conducted in the dedicated centers in the West 
elucidated a safer performance with a D2 or wider LND, with morbidity and hospital 
mortality being 17-22% and <2%, respectively, if resection of the pancreas and/or spleen 
was performed for selected patients.  
Considering that postoperative CRTx can be a substitution for a D2 LND, adjuvant CRTx 
constitutes an alternative option for countries where a D1 LND is the primary treatment or 
at institutions where surgeons are not keen on a D2, whereas its effect is questionable where 
a D2 dissection is both routine and safe -such as in Japan or in some Western specialized 
centers (Degiuli et al., 2004a; Degiuli et al., 2004b; Degiuli et al., 2010; Kulig et al., 2007; Sano 
et al., 2004; C.W.Wu et al., 2004; C.W.Wu et al., 2006). Interestingly, a Korean group (S.Kim 
et al., 2005) reported the superiority of adjuvant CRTx over surgery alone in gastric cancer 
patients undergoing a D2 dissection. Since the CRTx protocol in this study was identical to 
that of INT0116, the results, although observational, suggest that CRTx is promising even 
for patients undergoing a qualified LND.  
Two RCTs assessing the benefits of perioperative chemotherapy have been conducted. The 
MAGIC trial (Medical Research Council Adjuvant Gastric Infusional Chemotherapy) 
(Cunningham et al., 2006) was a randomized perioperative CTx trial in United Kingdom for 
patients with stage II or higher resectable adenocarcinoma of the stomach, esophagogastric 
junction, or lower esophagus. In this trial, the perioperative CTx consisted of three 
preoperative and three postoperative cycles of epirubicin, cisplatin, and fluorouracil (ECF). 
The perioperative CTx significantly improved 5-year DFS and 5-year OS. Another was a 
French trial (FNCLCC94012-FFCD9703) comparing perioperative cisplatin and 5FU (CF). 
Again, however, there are several limitations and criticisms regarding these trials. The scope 
of LND in MAGIC trial was not standardized, with a D1 or a D2 LND being left to the 
discretion of the surgeons, resulting in only 41% of the patients undergoing a D2 LND. 
Curative resection rates in the surgery only arm accounted only for 66% (MAGIC trial) or 
73% (FFCD trial) of the patients, suggesting that both were not purely adjuvant CTx trials 
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and likely recruited extremely advanced cases. Perioperative CTx may be harsh because of 
the relatively higher rate (9%) of not completing the three planned cycles of ECF, and of low 
rates of commencement (55%) and completion (42%) of the postoperative ECF, 
predominantly due to toxic effects, early disease progression, patient request, and 
postoperative complications. In addition, the 30-day mortality rate in both arms of the 
MAGIC trial was approximately 6%, which is relatively higher than those of a D2 (0-5%) 
(Degiuli et al., 2004a; Degiuli et al., 2004b; Degiuli et al., 2010; Kulig et al., 2007; Nashimoto 
et al., 2003; Sano et al., 2004; C.W.Wu et al., 2004; C.W.Wu et al., 2006) or wider scope of 
LND (0.8-2%) (Kulig et al., 2007; Sano et al., 2004) in Japanese and Western specialized 
institutions. Pathological T1 disease patients comprised 8% of the surgery only arm, 
suggesting that preoperative staging was not necessarily accurate and such earlier stage 
patients received unnecessary CTx, which would be more harmful than beneficial. Finally, 
the continuous infusion of 5FU that requires an infusion pump and long term infusional 
access may be associated with a risk of catheter-related complications. 
Taking these results concerning benefit and harm of LND into account, a D2 surgery is at 
least equal to an adjuvant CRTx with D0/D1 surgery, and an adjuvant S-1 improve 
survivals more than a D2 LND alone -at least in Japan. Encouraged by the positive results of 
INT0116 and MAGIC trials, a more combined multidisciplinary approach has been 
investigated in a CRITICS trial, in which adjuvant CRTx (investigational arm) after 3 
preoperative cycles of ECC (epirubicine, cisplatin, capecitabine) and D1 surgery (clearance 
of >15 nodes) was compared with 3 adjuvant cycles of ECC (control arm) after the same 
preoperative ECC and the same quality of surgery (http://www.critics.nl ). 
3.2 Advanced setting 
Evidence of benefits of CTx for patients with advanced or recurrent GC was obtained from 
the previous RCTs demonstrating a significantly improved survival by CTx as compared 
with the best supportive care (Glimelius et al., 1994; Murad et al., 1993; Pyrhönen et al., 
1995). In Western countries, FAMTX (5FU, adriamycin, methotrexate) then became the 
standard regimen from the results of the EORTC randomized study, demonstrating the 
superiority of FAMTX over FAM (5FU, adriamycin, mitomycin C) with regard to median 
survival time (MST) (42 weeks vs. 29 weeks), RR (41% vs. 9%), and toxicity (Wils et al., 
1991). Subsequently, a standard FAMTX regimen was compared with ECF. The RR and MST 
by ECF (46% and 8.7 months) were both found to be superior to FAMTX (21% and 6.1 
months) (Waters et al., 1999). In addition, ECF was less toxic, afforded patients better quality 
of life, and was more favorable in cost effectiveness as compared with FAMTX (Webb et al., 
1997), leading the investigators to propose an ECF regimen as a standard therapy. A recent 
systematic review revealed that the best survival results are achieved with a three-drug 
regimen containing 5FU, anthracycline, and cisplatin (Wagner et al., 2006). 
In this century, docetaxel, one of the new generation agents, has become available and been 
recognized as a promising agent, being incorporated in several clinical trials. The non-
overlapping toxicity profiles of docetaxel, cisplatin, and 5FU (DCF), as well as synergism 
among these agents in vitro (Maeda et al., 2004) in a schedule dependent manner or in 
human GC xenografts (Kodera et al., 2005), warrant this combination to be evaluated in 
treating GC. In Europe, a three-arm, randomized phase II study was conducted to compare 
DCF (docetaxel, cisplatin, 5FU), DC (docetaxel, cisplatin), and a standard reference regimen 
ECF (Roth et al., 2007). The RR and MST of the DCF (37% and 10.4 months) were superior to 
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those of the DC (18% and 11.0 months) and ECF (25% and 8.3 months), leading to the 
recommendation of DCF as an investigational regimen for further clinical trials. Similarly, in 
the United States, a randomized phase II trial found that DCF and DC were both active 
while DCF produced higher RR (43%) than DC (26%) (Ajani et al., 2005b). The DCF was then 
further positioned as an investigational regimen in a subsequent phase III trial (Van Cutsem 
et al., 2006), in which DCF was found to be significantly superior to CF with regard to RR 
(37% vs. 25%, p=0.01) and MST (9.2 months vs. 8.6 months, p=0.02). In addition, DCF was 
able to maintain patient performance status longer. However, a higher incidence of grade 
3/4 hematological toxicities (82% of neutropenia, 65% of leucopenia, and 29% of 
neutropenic fever) emphasized a need for a vigilant patient selection and careful patient 
management and monitoring, which might preclude its more widespread acceptance as a 
new treatment option.  
The requirement for a balance between survival gains and experienced toxicities has 
prompted several modifications of the DCF regimen to improve tolerability. A weekly 
administration of DCF may yield an improved safety profile without compromising the 
efficacy. In lung, breast, and prostate cancers, toxicities were less with weekly taxane than 
with triweekly taxane, while OS did not significantly differ between the two schedules or 
was even better in weekly taxane (Bria et al., 2006; Engels & Verweij, 2005; Sparano et al., 
2008). There are several trials of DCF modifications (C.P. Li, 2010; Lorenzen et al., 2007; 
Overman et al., 2010; Park et al., 2005; Sato et al., 2010; Tebbutt et al., 2010). Among these 
investigations, GASTRO-TAX-1 (Lorenzen et al., 2007) proved modified DCF to have a 
remarkably prolonged MST (17.9 months) and median time to progression (TTP) (9.4 
months), with a reduced incidence of grade 3/4 neutropenia (22%) and febrile neutropenia 
(5%).  
On the other hand, in Japan, JCOG conducted a randomized study comparing mitomycin C 
(MMC) plus tegafur with MMC plus UFT (uracil and tegafur) (UFT-M). Although MSTs 
were equivalent in both arms (6 months), significantly higher RR (25%) in the UFT-M arm 
than in the MMC plus tegafur arm (8%) (Kurihara et al., 1991) led the investigators to 
recommend UFT-M as a candidate regimen for further clinical trials. JCOG then conducted a 
three-arm RCT comparing UFT-M, CF, and a continuous infusion of 5FU (JCOG9205) 
(Ohtsu et al., 2003). In this trial, patient recruitment for the UFT-M arm was stopped due to 
poor survivals with significant toxicities, and the survival curves of the remaining two arms 
were overlapping. Taking efficacy and toxicity together into account, a continuous infusion 
of 5FU monotherapy with a MST of 7.1 months remained as a reference arm for further 
clinical trials.  
At the end of the last century, when S-1 became available, JCOG conducted another three-
arm RCT comparing the continuous infusion of 5FU monotherapy (reference regimen) with 
S-1, or irinotecan plus cisplatin (JCOG9912) (Boku et al., 2009). The investigators observed a 
noninferiority of S-1 to 5FU, and the convenience of oral administration lead to the 
conclusion that a continuous infusion of 5FU monotherapy could be replaced by S-1 for the 
first-line CTx.  
Encouraged by these results, several randomized trials have been conducted by placing S-1 
as a reference arm, and some trials have recently yielded results (Y.H. Kim et al., 2011; 
Koizumi et al., 2008; Narahara et al., 2011). Taking all these into account, a S-1 plus cisplatin 
combination (CS) is currently considered as a standard regimen in Japan for the treatment of 
advanced GC.  
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Globally, this combination has been investigated in a FLAGS study (First Line Advanced 
Gastric Cancer Study) (Ajani et al., 2010), in which 1053 patients were randomly assigned to 
either receive infusional CF or CS in non-Asian patients. Unfortunately, CS failed to prolong 
MST (8.6 months) as compared with CF (7.9 months). However, significant safety 
advantages of CS over CF suggested the possibility of the substitution of S-1 for infusional 
5FU. The different results between the Japanese SPIRITS trial and Caucasian FLAGS trial are 
ascribed to the different recommended doses of S-1 between the two studies, presumably 
due to different metabolic profiles among races. Tegafur, a cytotoxic component of S-1, is 
converted to 5FU by cytochrome P450 2A6 (CYP2A6). Racial differences for gene 
polymorphism of CYP2A6 have been identified (Yoshida et al., 2003) (Daigo et al., 2002; M. 
Nakajima et al., 2006), and the variants are more frequent in Asians than in Caucasians (M. 
Nakajima et al., 2006). Since such polymorphism accounts for a lower enzymatic activity, 
Caucasians have a relatively higher enzymatic activity than Asians, leading to a faster 
conversion from FT to 5FU, more accumulation of 5FU, and consequently less tolerance to S-
1. Accordingly, the recommended dose of S-1 in the FLAGS study (50mg/m2/day) was 
lower than that (80mg/m2/day) for Japanese (Ajani et al., 2005a). Another reason for the 
different results of the two trials may be the different ratio of patients receiving second-line 
therapies, which were respectively 74% and 75% in the CS and S-1 arms in the SPIRITS trial 
(Koizumi W et al., 2008), while they were respectively 30% and 33% in the CS and CF arms 
in the FLAGS trial (Ajani et al., 2010). 
In China, a similar randomized study is now ongoing. In this study, the S-1 dose is the same 
(80mg/m2/day, twice daily) as that in Japan, but cisplatin is given in four administrations, 
each being 20mg/m2 (http://www.ClinicalTrial.gov. NCT 01198392).  
Although the results of the FLAGS trial were unfortunately negative, an oral administration 
route is undoubtedly convenient; its advantages include the alleviation of the requirement 
for control of a central venous catheter implantation, which in turn may improve the 
patient’s quality of life. Against these backgrounds, there have been attempts to replace 
intravenous chemotherapy agents with the oral chemotherapy. Two-by-two designed RCTs 
(REAL-2 trial) have evaluated whether capecitabine (oral fluoropyrimidine) could be an 
alternative to infusional 5FU (Cunningham et al., 2008) and also whether cisplatin could be 
replaced by the new platinum compound oxaliplatin. In the REAL-2 study, the incorporated 
agents were epirubicin (E), cisplatin (C), 5FU (F), capecitabine (X), and oxaliplatin (O). Some 
1002 patients were randomly assigned to receive either one of triplet therapies such as ECF, 
EOF, ECX, and EOX. Interestingly, MST by EOX (11.2 months) was longer than that (9.9 
months) of a current European standard regimen ECF. Toxicities of capecitabine and 5FU 
were similar. Cisplatin requires hydration while oxaliplatin does not. As compared with 
cisplatin, oxaliplatin was associated with lower incidences of grade 3/4 neutropenia, 
alopecia, renal toxicity, and thromboembolism, but with higher incidences of grade 3/4 
diarrhea and neuropathy. These results, together with the results of the recent RCTs (Al-
Batran et al., 2008; Y.K. Kang et al., 2009), suggest the feasibility of substituting 5FU with 
capecitabine, or cisplatin with oxaliplatin. Indeed, the superiority of capecitabine over 5FU 
has been confirmed by a recent meta-analysis (Okines et al., 2009) 
Trends towards oral administration have prompted researchers to investigate whether 5FU 
can be replaced by oral fluoropyrimidine S-1 in the DCF regimen. Surprisingly, a 
combination of docetaxel, cisplatin, and S-1 (DCS) yielded remarkable RR (84%) and MST 
(23 months) (Sato et al., 2010). The optimal doses of docetaxel and/or cisplatin of this triplet 
therapy have been investigated in several phase I studies (Fushida et al., 2009; Hironaka et 
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al., 2010; Nakayama et al., 2008). No requirement of hydration in oxaliplatin has prompted 
the substitution of cisplatin with oxaliplatin in the DCS regimen, forming a new triplet 
docetaxel, oxaliplatin, and S-1. However, it achieved modest MST (12 months) with 38% 
grade 3/4 neutropenia, despite high RR and CR rates (60% and 7.5%) (Zang et al., 2010). 
Since these studies are preliminary, the efficacy and safety of DCS should be confirmed by 
large-scale clinical trials. Finally, a multicenter phase II trial has very recently demonstrated 
that an S-1 and oxaliplatin combination (SOX) can be a substitution for a CS regimen; this 
has just been indicated as a standard regimen in Japan or a safer regimen than FP in the 
West. The SOX regimen yielded remarkable MST (16.5 months), while grade 3/4 
neutropenia developed in 22% of the patients (Yamada et al., 2010).  
Another important concern lies in the fact that the net survival time cannot necessarily be 
achieved by a single regimen. As discussed earlier, negative results of the FLAGS trial may 
be attributable to the relatively small number of patients receiving second-line therapies. 
One should bear in mind that most of the chemotherapy regimens introduced above could 
yield a median TTP of less than 7 months, suggesting the urgent need for the establishment 
of effective second-line regimens. The contribution of a second line treatment on survival 
has been also confirmed by the combined analysis of two large Japanese randomized trials 
(JCOG9205 and JCOG9912) (Takashima et al., 2010). Because the number of active drugs 
against GC is increasing, attempts to establish the best second or third line regimen(s) are 
important, as has been seen for colorectal cancer as well. Currently, several RCTs have been 
conducted or are now ongoing to provide one answer for this unresolved issue. 
3.3 Neoadjuvant setting 
Many RCTs for neoadjuvant CTx (NAC) trials have been performed, but the majority have 
failed to provide evidence concerning the superiority of NAC as compared with controls 
(Hartgrink et al., 2004b; Imano et al., 2010; Nio et al., 2004; Schuhmacher et al., 2010; 
Yonemura et al., 1993; C.W. Zhang et al., 2004). The negative results may be accounted for 
by the small number of recruited patients -usually less than 200, heterogeneous tumor stage- 
i.e., some studies recruited earlier T1/T2 tumors, heterogeneity in the scope of the LND or 
drug administration route, and allowance of additional postoperative adjuvant therapies. 
Therefore, the NAC value remains controversial because of a lack of well-powered trials, 
and the results of several meta-analyses are conflicting (H. Li et al., 2010; W. Li et al., 2010; 
A.W. Wu et al., 2007). Although the most recent two analyses revealed benefits of NAC in 
terms of OS, resection rate, and tumor down staging without increasing perioperative 
mortality (H. Li et al., 2010; W. Li et al., 2010), the effect of NAC alone on OS remains 
questionable since individual pure NAC trials, i.e., comparison between surgery alone and 
NAC without postoperative CTx, failed to demonstrate positive effects on survival (W. Li et 
al., 2010). Similarly, surgery plus postoperative CTx with or without NAC provided similar 
survival results (Nio et al., 2004).  
As discussed in the General Considerations section, the selection of patients who receive the 
most benefit from NAC is an important concern (Table). The benefit of NAC was observed 
only in more advanced (T3/T4) cancers but not in earlier (T1/T2) cancers (W. Li et al., 2010), 
suggesting that any potential survival benefit may be confined to those patients at greatest 
risk of relapse (T3/T4). Whether early stage GC received the same benefit of NAC remains 
unclear since serosa-negative gastric cancer in Japan exhibited 83% DFS and 86% OS by a D2 
LND without adjuvant CTx (JCOG9206-1) (Nashimoto et al., 2003). Similar favorable 
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survival results by qualified surgery in earlier stage GC were also reported from the West 
(Roukos et al., 2001; Siewert et al., 1998), suggesting that patients with a low risk of 
recurrence can be cured with adequate surgery alone (Roukos, 2004). The benefit of NAC is 
also influenced by the quality of surgery. As discussed in the MAGIC trial, positive effects of 
NAC, if present when the combined surgery is a <D2 LND, can be attributable to a mere 
substitution for a LND rather than the effects of the NAC itself. When determining the NAC 
regimen, one providing the highest likelihood of tumor shrinkage is theoretically the best 
regimen for NAC because subsequent surgery can extirpate the residual disease of the NAC. 
In this sense, several NAC trials using CS, which provides currently the highest RR (74%) 
(Koizumi et al., 2003), are ongoing in Japan. First, JCOG0501 is a RCT comparing surgery 
alone with neoadjuvant CS for type 4 or large type 3 GC (http://www.ClinicalTrial.gov. 
NCT00252161). Second, JCOG0405 is a phase II study investigating the efficacy of 
neoadjuvant CS for GC with bulky second-tier nodes or positive paraaortic  
nodes (Kawashima et al., 2008). The third study is a comparison between surgery alone  
and neoadjuvant CS, both containing adjuvant S-1 for stage III GC 
(http://www.ClinicalTrial.gov. NCT00182611).  
4. Esophageal cancer 
4.1 Adjuvant setting 
In the West, a number of RCTs have been conducted to investigate the efficacy of adjuvant 
CTx or adjuvant RTx. A subsequent meta-analysis, however, failed to find any survival 
benefit at three years by adjuvant CTx or at one year by adjuvant RTx (Malthaner et al., 
2004). This conclusion concerning the efficacy of adjuvant CTx was, however, drawn from 
the pooled data of only 2 studies. So far, there have been no RCTs evaluating adjuvant CRTx 
versus surgery alone (Malthaner et al., 2004); however, several phase II trials have 
demonstrated that adjuvant CRTx appeared to prolong survival (Bédard et al., 2001; Rice et 
al., 2003).  
In Japan, an earlier RCT of adjuvant CTx consisting of cisplatin plus vindesine conducted in 
the 1980s failed to exhibit a survival benefit over surgery alone (JCOG8806) (Ando et al., 
1997). JCOG then conducted a RCT (JCOG9204) comparing adjuvant CF with surgery alone 
(Ando et al., 2003). Although 5-year SR did not differ between the two arms (p=0.13), 
adjuvant CF was able to yield significantly improved 5-year DFS (p=0.04), which was more 
evident in node positive patients. In Japan, no adequate RCTs have been conducted to assess 
adjuvant RTx or adjuvant CRTx as compared with surgery alone.  
4.2 Neoadjuvant setting  
Multimodal therapies as a neoadjuvant setting have been developed mostly in the West, but 
their efficacy is conflicting. The significance of survival prolongation by NAC has changed 
from inconclusive in earlier metaanalyses (mortality hazard=0.88, 95% CI=0.75-1.04) 
(Malthaner et al., 2004; Malthaner et al., 2006) to just reaching positive (mortality 
hazard=0.90, 95% CI=0.81-1.00, p=0.05) (Gebski et al., 2007). The significance was more 
evident in adenocarcinomas by subgroup analyses by histology (mortality hazard=0.78, 
CI=0.64-0.95, p=0.014) (Gebski et al., 2007). Fortunately, treatment morbidity and mortality 
did not differ between NAC and surgery alone (Malthaner et al., 2006; Urschel et al., 2002). 
However, the positive NAC effects on survival (Gebski et al., 2007) seem to be influenced by 
one MRC study (Medical Research Council Oesophageal Cancer Working Group 2002) with 
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the largest sample size (n=802), while most of the included RCTs in this meta-analysis in 
which the number of recruited patients was less than 100 showed no or marginal benefit for 
NAC. Although the survival benefit of the MRC study has been recently confirmed by a 
long-term follow-up study (Allum et al., 2009), the interpretation of this study requires 
caution, because the 5-year SR of the surgery only arm was only 17% despite half of the 
recruited EC being T3 or less (Medical Research Council Oesophageal Cancer Working 
Group 2002). This low SR contrasts with that (52%) of the surgery only arm in the JCOG9204 
study, in which 65% and 55% of patients had T3/T4 and stage III/IV diseases, respectively. 
Conceivably, the advantage of neoadjuvant treatment is more likely to be demonstrated 
when SR in the control (surgery only) arm is lower. In addition, the survival benefit initially 
observed in adenocarcinoma in the MRC study disappeared in the later analysis (Allum et 
al., 2009). Finally, although NAC could enhance the chance of R0 resection, the pattern of the 
first recurrence was similar between the neoadjuvant CTx arm and surgery only arm (Allum 
et al., 2009), suggesting that NAC showed no clear trend toward fewer patients with distant 
metastasis as the first site of metastasis. These characteristics were also confirmed in the 
second largest study (RTOG8911) (Kelsen et al., 1998). 
There are several systematic overviews concerning neoadjuvant RTx. These studies have 
consistently failed to reveal any improvement of survival by neoadjuvant RTx in patients 
with potentially resectable EC (Arnott et al., 2005; Ask et al., 2003; Malthaner et al., 2004).  
In contrast, there are increasing expectations for neoadjuvant CRTx which are also 
supported by a recent RCT showing that neoadjuvant CRTx resulted in a significantly 
higher pathological CR rate compared with neoadjuvant CTx (Stahl et al., 2009). This could 
translate into a marginally significant (p=0.07) improvement in 3-year SR from 28% in 
neoadjuvant CTx to 47% in neoadjuvant CRTx in patients with locally advanced 
adenocarcinomas of the esophagogastric junction. Although some inconsistencies do exist 
(Luu et al., 2008), several neoadjuvant randomized CRTx trials have been conducted in the 
West and elucidated the rates of downstaging (Fiorica et al., 2004), R0 resection (Urschel & 
Vasan, 2003), and 3-year survival (Fiorica et al., 2004; Urschel & Vasan, 2003) in favor of 
neoadjuvant CRTx. Such survival benefits in favor of neoadjuvant CRTx were observed in 
both adenocarcinoma and squamous cell carcinoma (Gebski et al., 2007). 
In Japan, the results of JCOG9204 have led to the subsequent RCT (JCOG9907) to determine 
which timing of the CTx administration is optimal, preoperatively or postoperatively. 
Preoperative CF was superior to postoperative CF both in progression free survival (PFS) 
(p=0.044) and OS (p=0.014), suggesting that neoadjuvant CF is superior to adjuvant CF or 
surgery alone. Whether the novel active regimen such as DCF or weekly DCF in GC can be 
extrapolated to EC has been investigated in a phase I/II trial (JCOG0807).  
Comparing Japanese trials with Western ones, one should notice the dramatic difference in 
terms of postoperative mortality and survival outcomes. In Japan, surgery with at least 2-
field LND yielded >50% 5-year SR with extremely low mortality, while Western studies 
demonstrated increased mortality (>5%) with lower 5-year SR. In addition, neoadjuvant 
CRTx resulted in increased postoperative in-hospital mortality than surgery alone (Fiorica et 
al., 2004), due to the three most frequent adverse events of respiratory complications, heart 
failure, and anastomotic leakage (Fiorica et al., 2004). As discussed in the General 
Considerations section, 3-field LND realizes local control, so that neoadjuvant CTx can 
afford a most impressive survival advantage and be regarded as a new standard regimen in 
stage II/III squamous cell carcinoma in Japan. 
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4.3 Definitive CRTx for resectable EC 
CRTx only (definitive CRTx) undoubtedly represents an alternative treatment for patients 
with EC considered unsuitable for surgery on the basis of comorbidity, poor performance 
status, and locoregional diseases too extensive for curative resection. For respectable EC, 
although esophagectomy has still been designated as -at least a part of- a pivotal treatment 
modality, it is indeed a complex, highly invasive procedure. Operative morbidity and 
mortality undoubtedly depend on hospital volume; however, reports on this topic from the 
West, some of which were from high volume centers, documented a near 50% morbidity 
and 10% mortality (Bailey et al., 2003; Birkmeyer et al., 2002; Jamieson et al., 2004). Since 
CRTx does have a significant downstaging effect but increases postoperative mortality when 
combined with surgery, there is growing enthusiasm for the definitive CRTx to treat 
potentially resectable EC. The choice of CRTx as a definitive treatment option is based on 
the RTOG 8501 trial, which was instrumental in defining the superiority of definitive CRTx 
with a 50Gy radiation dose over definitive 64Gy RTx alone (Herskovic et al., 1992). A 
subsequent metaanalysis has confirmed its promise (Wong & Malthaner, 2006).  
Two large RCTs examined whether surgery was necessary after CRTx. A German group 
demonstrated similar 2-year SR in the neoadjuvant CRTx to a total dose of 40Gy followed by 
surgery (40%), and in the definitive CRTx with at least 65Gy (35%) in locally advanced 
squamous cell cancer (Stahl et al., 2005). A subsequent French trial (FFCD9102) (Bedenne et 
al., 2007; Bonnetain et al., 2006) also confirmed no benefit for additional surgery after CRTx 
to the responding patients with locally advanced squamous cell cancer. In addition, a 
nonrandomized comparison revealed the same impact on survival between definitive CRTx 
and surgery only (without adjuvant treatment) (Hironaka et al., 2003). A single arm phase II 
study in Japan (JCOG9906) (K. Kato et al., 2010) demonstrated that definitive CRTx in stage 
II/III esophageal squamous cell cancer could yield a complete response rate of 62%, with 3-
year and 5-year SR being 45% and 37%, respectively, comparable to those for 
esophagectomy (33-47% and 20-52%, respectively) (The Japan Esophageal Society). 
However, these findings are still inferior to those of the neoadjuvant CF arm in the JCOG 
9907 trial. Accordingly, definitive CRTx is not regarded as a standard treatment for stage 
II/III esophageal squamous cell cancer in Japan.  
Nevertheless, these encouraging reports have led to the further activation of several studies 
to assess the efficacy of definitive CRTx for patients with earlier stage squamous cell cancer. 
JCOG9708 trial (H. Kato et al., 2009) elucidated 2-year and 4-year SRs of 93% and 81%, 
respectively, which were comparable to those of the stage I SCC undergoing esophagectomy 
(The Japan Esophageal Society). Other investigators also reported a high complete response 
rate (88%) and 3-year SR (79%) in patients with stage I SCC by definitive CRTx (Minashi et 
al., 2006). However, definitive CRTx is accompanied by several problems.  
First, and unfortunately, crude locoregional control rates remain poor, with a respective 23-
65% and 13-67% of patients having persistent disease or relapse at the primary site (Coia et 
al., 2000; Cooper et al., 1999; Minsky et al., 2002; Murakami et al., 1998; Stahl et al., 2005; K.S. 
Wilson & J.T. Lim, 2000). Tumor recurrence among patients whose treatment results 
deemed CR is a problem with definitive CRTx because no perfect diagnostic methods 
currently exist for the evaluation of CR. In the JCOG 9708 trial, although the complete 
response rate was high (88%), half of the total patients relapsed. In another definitive CRTx 
trial (Minashi et al., 2006), locoregional diseases were discovered later in 14 (39%) of 36 
complete response patients. Although surgery is not intended as part of the definitive CRTx, 
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salvage surgery that could offer the only chance of cure for patients with recurrent or 
residual diseases after definitive CRTx should be considered. In addition, definitive CRTx-
related local complications such as esophageal stenosis and perforation are also indications 
for salvage surgery. However, salvage surgery is a highly invasive and complex treatment 
leading to increased morbidity (50-79%) and in-hospital mortality (7-22%) as compared with 
those after neoadjuvant CRTx, due to the adverse events of predominantly respiratory 
complications and anastomotic leakage (Chao et al., 2009; Nakamura et al., 2004; M. 
Nishimura et al., 2007; Oki et al., 2007; Smithers et al., 2007; Swisher et al., 2002; Tachimori et 
al., 2009; Tomimaru et al., 2006). These hospital mortality rates are obviously higher than 
those for esophagectomy in Japan reported from specialized centers (2%) (Tachimori et al., 
2009) or the nationwide registry (5%) (The Japan Esophageal Society). Second, definitive 
CRTx for resectable EC has the merit of preserving the esophagus, though it may increase 
late toxicity such as pericardial or pleural effusion (Ishikura et al., 2003; Kumekawa et al., 
2006). Pericardial and pleural effusion developed in nearly 20% of complete response 
patients, leading to 10-12% of treatment-related deaths (Ishikura et al., 2003; Kumekawa et 
al., 2006). Even in the earlier stage squamous cell cancer, definitive CRTx-related mortality 
was observed in 8% of complete response patients (Minashi et al., 2006). These facts suggest 
that late toxicities are often progressive in severity and may compromise the long term 
health-related quality of life of a cancer survivor, leading to nullifying the anticipated 
treatment benefit from therapy. Since conventional toxicity reporting tends to present the 
more intensive treatments as less toxic than they really are (Trotti et al., 2007), one should 
bear in mind that the actual toxicities are likely to be underestimated.  
These complications are accounted for by the radiation per se that renders risks of 
pulmonary complications, partly due to the fibrogenic response pathway (Bentzen, 2006), 
and the radiation induced injury in the thoracic cavity that makes surgical procedures 
technically more difficult and subsequently increases bleeding. In addition, the irradiated 
stomach, esophagus, and trachea become fragile with the impaired blood supply that 
eventually causes anastomotic leakage or conduit necrosis. The incidences of morbidity after 
salvage surgery were associated with radiation doses rather than clinical factors (Wang et 
al., 2006), suggesting that a dosimetric aspect should be taken into account in planning a 
definitive CRTx. On this basis, several attempts have been made to reduce the incidences of 
postoperative morbidity and mortality of salvage surgery. RTOG94-05/INT0123 elucidated 
the possibility of total radiation volume reduction (50.4Gy), which was equally effective as 
compared with higher doses (64.8Gy) (Minsky et al., 2002). A novel radiation technique has 
been developed to ensure an increased volume of lung unexposed to radiation to deliver 
large and uniform doses to the tumor while sparing nearby normal tissues (X. Zhang et al., 
2008). In Japan, based on the phase I study results (T.E. Nakajima et al., 2009), a phase II 
study of definitive CRTx with a radiation dose of 50.4Gy for stage II/III esophageal 
squamous cell cancer is ongoing (JCOG0909). In planning a definitive CRTx, therefore, a 
higher radiation dose is not recommended because it does not improve survival but would 
presumably increase the risks of salvage surgery if needed.  
Given the highly invasive and formidable procedures of salvage surgery, patient selection of 
those who would receive the most benefit or who would be unfit for surgery is a major 
concern in the clinical field. Several factors have been proposed for patient selection for 
salvage surgery. First, there is some evidence that patients with recurrence after CRTx had a 
significantly better survival after salvage surgery than those with persistent disease (Swisher 
et al., 2002). Salvage surgery could be avoided in complete response patients, but the 
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diagnosis of complete response by imaging is not always reliable and is possible merely by 
resected specimen. Indeed, 10-13% of patients undergoing salvage surgery were proved to 
have pathologically complete response (Murakami et al., 1998; M Nishimura et al., 2007; 
Tachimori et al., 2009). Unfortunately, positron emission tomography using 2-[fluorine-18]-
fluoro-2-deoxy-D-glucose (FDG-PET) (Klaeser et al., 2009) or its combination with other 
imaging modalities such as computed tomography and/or endoscopic ultrasonography 
(Swisher et al., 2004) failed to distinguish between patients with >10% viable cells and those 
with <10% viable cells, resulting in a false negative rate of 16-31% by each modality (Swisher 
et al., 2004). In this study, the accuracy rates decreased dramatically when an attempt was 
made to distinguish microscopic residual disease (1% to 10% viable cell) from the “true” 
pathological complete response (0% viable cells), implying that these modalities have 
limited value for response assessment for patients receiving preoperative treatment. 
Consequently, patients whose tumor response is deemed complete response after CRTx 
could have residual diseases and not be ascribed a reason to preclude further additional 
treatment. To solve these drawbacks, recent research has focused on the gene expression 
that can predict CRTx response (Eschrich et al., 2009; He et al., 2009; Maher et al., 2009). 
Second, multivariate analysis revealed that the most significant factor associated with long-
term survival was a R0 resection (Chao et al., 2009; Tomimaru et al., 2006). No patients left 
with gross or microscopic residual tumors after salvage surgery (R1/R2 resections) survived 
more than 24 months in any series (Chao et al., 2009; Nakamura et al., 2004; Oki et al., 2007; 
Swisher et al., 2002; Tachimori et al., 2009; Tomimaru et al., 2006). However, the R1/R2 
resection rate has been substantially high, ranging from 15-50% (Chao et al., 2009; 
Nakamura et al., 2004; Oki et al., 2007; Swisher et al., 2002; Tachimori et al., 2009; Tomimaru 
et al., 2006), and the resection status cannot be confidently predicted before surgery or even 
during surgery because of the indistinct planes between tumor and fibrotic masses within 
the irradiated mediastinum. Therefore, FDG-PET or other imaging modalities are used to 
select patients who are absolutely unfit for salvage surgery. There is an urgent need for the 
development of more reliable, accurate diagnostic tools for the assessment of response and 
resection status prediction.  
5. Molecular targeting therapy 
Despite the many challenges for establishment of more active multimodal therapy regimens, 
the mean average survival benefit remains only slight in GC and EC. The MST remains 
consistently around or less than 12 months in metastatic GC and EC (Ishida et al., 2004; 
Koizumi et al., 2008; Y. Nishimura et al., 2002; Ohtsu et al., 1999), underscoring a need for 
more active new agents and regimens. Against these backgrounds, a new generation of 
therapies designed to target epidermal growth factor receptor (EGFR) and subsequent 
cellular responses, or angiogenic processes, which both involve and promote tumor growth 
and survival, have been very recently introduced.  
There are several approaches to target EGFR or angiogenic processes. First is monoclonal 
antibodies against EGFR, including cetuximab (a chimeric monoclonal immunoglobulin G1 
antibody), panitumumab (a fully human monoclonal immunoglobulin G2 antibody), and 
trastuzumab (a monoclonal antibody against human epidermal growth factor receptor-2 
(HER2)). Second is an inhibition of the tyrosine kinase (TK) domain and subsequent signal 
cascade; the molecules which play the role include gefitinib, erlotinib (both are inhibitors of 
EGFR-TK), lapatinib (a dual inhibitor of HER2-TK and EGFR-TK), sunitinib (inhibitor of TK 
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of various kinds of proteins), and everolimus (RAD001) (inhibitor of mammalian target of 
rapamycin). Third is an inhibitor of tumor vascularization to anticipate the prevention of 
eventual tumor invasion and metastasis such as bevacizumab, a monoclonal antibody 
developed to target vascular endothelial growth factor (VEGF). There are several planned or 
ongoing RCTs incorporating molecular targeting therapies, and some trials have provided 
encouraging results.  
5.1 Anti-EGFR antibody 
A positive HER2 protein or amplified HER2 gene was observed in approximately 20% of GC 
patients (Jørgensen, 2010). An efficacy of trastuzumab for GC has been very recently 
demonstrated by a global RCT (ToGA trial; NCT01041404) which has revealed a 
significantly (p<0.005) prolonged MST (13.8 months) and RR (47%) by adding trastuzumab 
to 5FU (or capecitabine) and cisplatin as compared with those (11.1 months and 35%) 
without trastuzumab (Bang et al., 2010). However, it should be noted that the RR by adding 
trastuzumab to CTx was at best 50% even among the HER2 positive GC patients. 
Furthermore, the improvement of MST (13.8 months) was -although promising- only 
marginal as compared with those of a CS in SPIRITS trial (Koizumi et al., 2008). 
Furthermore, subanalysis by region revealing the efficacy of adding trastuzumab was 
observed in Europe and Central/South America but not in Asia. Considering that second-
line treatment was performed more in Asia than in Europe or Central/South America, the 
power of second-line therapy in the control (without trastuzumab) arm may bring the 
treatment results of the two arms closer, leading to non-significant results in Asia. 
5.2 Anti-VEGF antibody 
The AVAGAST trial (NCT00548548) is the first RCT investigating the efficacy of 
bevacizumab, in which GC patients were randomized to 5-fluorouracil (or capecitabine) and 
cisplatin with or without bevacizumab (Y. Kang et al., 2010). Adding bevacizumab achieved 
a longer PFS (6.7 months vs. 5.3 months) and higher overall RR (38% vs. 30%); however, it 
failed to produce significant MST prolongation (12.1 months vs. 10.1 months). Several 
explanations are possible for these negative results. The results appeared to differ among 
subgroups according to geographic region. As was seen in the ToGA trial, adding 
bevacizumab proved to be effective in the pan-American region and in Europe but not in 
Asia, reflecting the role of a second-line treatment (van Cutsem et al., 2010). Alternatively, a 
potential disadvantage of the AVAGAST trial is a lack of a specific target that would allow 
for the optimal patient selection that was possible in the ToGA trial.  
6. Future perspectives 
While many regimens incorporating multimodal therapies have been investigated, it is also 
true that there is a great variability in tumor response and patient survival among regimens. 
In addition, even among patients receiving the same regimen, a given regimen may prove 
too active or too toxic for an individual. Unfortunately, however, it is difficult to predict 
perfectly the efficacy and toxicity prior to therapy. Therefore, there is a pressing need to 
explore the molecules and genes that could help explain the interindividual differences in 
drug response and toxic events. Such a discovery and validation of predictive biomarkers 
could allow us to develop a model for selecting the optimal therapy on an individual basis 
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and reduce morbidity and reduce health care costs by avoiding potentially unnecessary or 
futile treatment, ultimately allowing treatment to be individualized (Shimoyama, 2009). 
One example is a predictive role of a biomarker in the usage of anti-EGFR therapy. Since 
mutant K-Ras or mutant B-Raf causes cells to escape from adequately controlled cell 
proliferation and consequently confers resistance to anti-EGFR therapies, K-Ras (Lièvre et 
al., 2008) or B-Raf (Tol et al., 2009) is considered a negative predictor for the efficacy of anti-
EGFR therapy such as cetuximab and panitumumab in colorectal cancer (Allegra et al., 2009; 
Amado et al., 2008; Jiang et al., 2009). In contrast, incidences of K-Ras mutation were 3-21% 
in GC (Hongyo et al., 1995; I.J. Kim et al., 2003; Lee et al., 2003; Yoo et al., 2002; W. Zhao et 
al., 2004) and 0-9% in EC (Janmaat et al., 2006; Lorenzen et al., 2009), both relatively low as 
compared with those of colorectal cancer (Andreyev et al., 1998). In addition, the predictive 
value of the K-Ras mutation concerning the efficacy of anti-EGFR therapy has not been 
clearly established in esophagogastric cancer (Park et al., 2010). Furthermore, incidences of 
B-Raf mutation in GC were also low (2.2-3%). Therefore, whether mutations of K-Ras or B-
Raf as negative predictors seen in colorectal cancer can be extrapolated into gastric and 
esophageal cancers requires further study. Actually, current phase III trials of cetuximab or 
panitumumab in GC and EC allow the inclusion of patients irrespective of K-Ras mutation 
status or EGFR immunohistochemical positivity. In addition, since racial difference does 
exist in some drug metabolizing enzymes (Shimoyama, 2010), the usefulness of predictive 
biomarkers may differ between Western and Eastern hemispheres as well as between tumor 
types. 
Another perspective is the incorporating of molecular targeting therapy or other agents into 
conventional therapy. As discussed in the INT0116 trial, new generation agents with 
radiosensitizing effects should be continuously incorporated into future clinical trials. 
Accordingly, several promising results have been reported by the use of new generation 
agents in combination with molecular targeting therapy, or with radiation, or both (Gaast et 
al., 2010; Knox et al., 2010; Pinto et al., 2007; Safran et al., 2008; Spigel et al., 2010; Syrigos et 
al., 2008). Furthermore, non-cytotoxic agents such as statins are theoretical candidates for 
overcoming current problems of molecular targeting therapy (Shimoyama, 2011).  
It is impossible to conduct RCTs for exhaustive drug combinations. There must be 
continuing efforts to obtain knowledge on specific drug interactions that could bypass 
clinical trials from one administration schedule to another or from one tumor type to 
another. This stance may most efficiently facilitate the establishment of the best multimodal 
therapies.   
7. Conclusion 
In GC, recent RCTs have elucidated the promising efficacy of multimodal therapies in an 
adjuvant and advanced settings, where S-1 plays a pivotal role in these settings. This is in 
agreement with the recent stance in which oral administration takes advantage over the 
intravenous administration. In EC, CRTx in neoadjuvant or definitive setting has gained the 
most intensive research topic; however, the latter setting is inevitably associated with highly 
morbid salvage surgery. Furthermore, researches in novel targeted therapies against growth 
signal transduction cascade have just begun and their efficacy has been anticipated.  
For the treatment of GC and EC, we should say “good-by” for the surgery only treatment 
era while the “multimodal treatment era” is welcomed. It is hugely encouraged to consider 
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multimodal therapies on the adjuvant, neoadjuvant, and advanced settings, as well as by the 
usage of conventional treatment (CTx, RTx, and CRTx) and targeted therapies, alone or in 
combination. Recent attempts have continuously clarified the molecular profiles or genetic 
events to stratify patients who receive the best benefit, which realizes maximization of the 
treatment effects instead of “one-regimen-fits-all” stance.  
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